What is retatrutide?
Also known as: Reta
- Route
- Subcutaneous
- Half-life
- ~6 days
- Evidence
- Growing evidence
Investigational triple-receptor compound (GLP-1, GIP, glucagon). Discussed around weight and metabolism.
Retatrutide is a newer compound that acts on three receptors: GLP-1, GIP, and glucagon. That triple action is what people point to when they discuss it, usually in the context of weight loss and metabolism.
It is still being studied, so its evidence base is younger than semaglutide's or tirzepatide's. TRKD+ marks it Growing to reflect that.
Retatrutide is investigational rather than a widely approved prescription product, so anything about using it is a conversation for a licensed provider. TRKD+ describes it and lets you track it. It does not recommend or prescribe.
Vocabulary
Terms you’ll see with it.
- Protocol
GLP-1 agonist
A class of drugs (semaglutide, tirzepatide) that mimic a gut hormone tied to appetite.
- Protocol
Titration
Easing a dose up or down gradually over weeks, rather than jumping straight to a target.
- Route
Subcutaneous
Injected into the fat layer just under the skin. Short needle, shallow angle.
- Timing
Half-life
How long it takes for half of a dose to clear your system. Drives dosing frequency.
Common questions
People also ask.
- What makes retatrutide different from semaglutide?
- Retatrutide acts on three receptors (GLP-1, GIP, glucagon); semaglutide acts on one (GLP-1).
- Is retatrutide approved?
- It is still investigational and under study rather than a widely approved prescription product.
TRKD+
Track the whole stack, calmly.
Log peptides, GLP-1s, and TRT. Rotate injection sites. Free, private, no ads.